Journal article

Cognitive and neuropsychiatric disease manifestations in MS

A Feinstein, J DeLuca, BT Baune, M Filippi, H Lassman

Multiple Sclerosis and Related Disorders | ELSEVIER SCI LTD | Published : 2013

University of Melbourne Researchers

Grants

Funding Acknowledgements

Dr. Feinstein has served on scientific advisory boards for Merck Serono and Avanir Pharmaceuticals; has received speaker honoraria from Merck Serono, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Biogen Idec; serves on the editorial boards of Multiple Sclerosis and the African Journal of Psychiatry; receives publishing royalties for The Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press, 2007); serves on the Medical Advisory Committee for the Multiple Sclerosis Society of Canada; conducts neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry in his clinical practice (20% effort); and receives research support from Teva Pharmaceutical Industries Ltd., Merck Serono, Canadian Institute of Health Research, and the Multiple Sclerosis Society of Canada. Dr. J. DeLuca reports no disclosures. Dr. B. Baune reports no disclosures. Dr. M. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompe, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves as Co-Editor in Chief for Journal of Neurology; serves on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Neuroimaging, Journal of Neurovirology, The Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences; serves as a consultant to Bayer Schering Pharma, Biogen-Dompe, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on speakers bureaus for Bayer Schering Pharma, Biogen-Dompe, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompe, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd. and Fondazione Italiana Sclerosi Multipla. Dr. H. Lassman reports no disclosures.